Research Article

Association between obesity profile and non-alcoholic fatty liver by race/ethnicity

Martin Galindo, Katrina M Schrode and Magda Shaheen*

Published: 19 January, 2021 | Volume 5 - Issue 1 | Pages: 001-010

NAFLD is characterized by accumulation of fat in the liver that can lead to health complications. Previous studies have found the obesity phenotype and its components to be risk factors for the development of NAFLD. This study aims to examine the relationship between the obesity phenotype and NAFLD among each racial-ethnic group. We analyzed data from the NHANES III survey (1988-1994). The obesity phenotype was defined based on BMI and metabolic syndrome. NAFLD was defined by abdominal ultrasounds among non-alcoholics with no infection or taking drugs affecting the liver. A higher prevalence of NAFLD was found among the metabolically unhealthy obese group (43.1%) and the metabolically unhealthy overweight (29.4%) than the metabolically unhealthy normal weight (11.8%). Mexicans-Americans had higher odds of NAFLD relative to whites (adjusted odds ratio (AOR) = 1.3, 95% confidence interval (CI) = 1.01-1.9, p = 0.04). The metabolically healthy obese phenotype was associated with NAFLD (p > 0.05) in the overall sample and in Whites. The metabolically healthy overweight was associated with NAFLD only among Mexican-American (p < 0.05). Metabolically unhealthy overweight or obese had higher odds of NAFLD relative to the metabolically healthy normal weight and this relation is consistent in all the racial/ethnic groups (p < 0.05). Metabolically healthy overweight and obese individuals had a high chance of NAFLD and it varied by race/ethnicity. Healthcare providers should pay more attention to care for those who are part of the metabolically healthy overweight or obese group especially among the Mexican-American population.

Read Full Article HTML DOI: 10.29328/journal.acem.1001017 Cite this Article Read Full Article PDF


  1. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014; 28: 637-653. PubMed: PubMed: https://pubmed.ncbi.nlm.nih.gov/25194181/
  2. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67: 328-357. PubMed: PubMed: https://pubmed.ncbi.nlm.nih.gov/28714183/
  3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-344. PubMed: PubMed: https://pubmed.ncbi.nlm.nih.gov/23507799/
  4. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004; 164: 2169-2175. PubMed: PubMed: https://pubmed.ncbi.nlm.nih.gov/15505132/
  5. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007; 11: 105-117. PubMed: PubMed: https://pubmed.ncbi.nlm.nih.gov/17544974/
  6. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease. 2015; 47: 181-190. PubMed: PubMed: https://pubmed.ncbi.nlm.nih.gov/25739820/
  7. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37: 917-923. PubMed: https://pubmed.ncbi.nlm.nih.gov/12668987/
  8. Cotrim HP, Parise ER, Oliveira CP, Leite N, Martinelli A, et al. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Ann Hepatol. 2011; 10: 33-37. PubMed: https://pubmed.ncbi.nlm.nih.gov/21301007/
  9. Goossens GH. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. Obes Facts. 2017; 10: 207-215. PubMed: https://pubmed.ncbi.nlm.nih.gov/28564650/
  10. Park J, Kim SH, Cho GY, Baik I, Kim NH, et al. Obesity phenotype and cardiovascular changes. J Hypertens. 2011; 29: 1765-1772. PubMed: https://pubmed.ncbi.nlm.nih.gov/21826021/
  11. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metabol. 2006; 91: 2906-2912. PubMed: https://pubmed.ncbi.nlm.nih.gov/16735483/
  12. Kabootari M, Akbarpour S, Azizi F, Hadaegh F. Sex specific impact of different obesity phenotypes on the risk of incident hypertension: Tehran lipid and glucose study. Nutrition Metabol. 2019; 16: 16.
  13. Chang Y, Jung HS, Yun KE, Cho J, Ahn J, et al. Metabolically healthy obesity is associated with an increased risk of diabetes independently of nonalcoholic fatty liver disease. Obesity. 2016; 24: 1996-2003. PubMed: https://pubmed.ncbi.nlm.nih.gov/27474900/
  14. Shaharyar S, Roberson LL, Jamal O, Younus A, Blaha MJ, et al. Obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are significantly associated with prevalence of elevated C-reactive protein and hepatic steatosis in a large healthy Brazilian population. J Obes. 2015; 2015. 178526. PubMed: https://pubmed.ncbi.nlm.nih.gov/25838943/
  15. Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol. 2012; 107: 561-567. PubMed: https://pubmed.ncbi.nlm.nih.gov/22108448/
  16. Stefan N, Schick F, Haering HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metabol. 2017; 26: 292-300. PubMed: https://pubmed.ncbi.nlm.nih.gov/28768170/
  17. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15: 11-20. PubMed: https://pubmed.ncbi.nlm.nih.gov/28930295/
  18. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012; 91: 319-327. PubMed: https://pubmed.ncbi.nlm.nih.gov/23117851/
  19. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol. 2004; 99: 292-298. PubMed: https://pubmed.ncbi.nlm.nih.gov/15046220/
  20. Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018; 16: 198-210. PubMed: https://pubmed.ncbi.nlm.nih.gov/28970148/
  21. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40: 1461-1465. PubMed: https://pubmed.ncbi.nlm.nih.gov/18820647/
  22. Petersen R, Pan L, Blanck HM. Peer Reviewed: Racial and Ethnic Disparities in Adult Obesity in the United States: CDC’s Tracking to Inform State and Local Action. Prevent Chronic Dis. 2019; 16: E46. PubMed: https://pubmed.ncbi.nlm.nih.gov/30974071/
  23. Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US AdultsFindings From the Third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356-359. PubMed: https://pubmed.ncbi.nlm.nih.gov/11790215/
  24. Heiss G, Snyder ML, Teng Y, Schneiderman N, Llabre MM, et al. Prevalence of Metabolic Syndrome Among Hispanics/Latinos of Diverse Background: The Hispanic Community Health Study/Study of Latinos. Diabetes Care. 2014; 37: 2391-2399. PubMed: https://pubmed.ncbi.nlm.nih.gov/25061141/
  25. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index; United States. 2003-2006. Natl Health Stat Report. 2009; 5: 1-7. PubMed: https://pubmed.ncbi.nlm.nih.gov/19634296/
  26. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310: 2191-2194. PubMed: https://pubmed.ncbi.nlm.nih.gov/24141714/
  27. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 1. 1994: 1-407. PubMed: https://pubmed.ncbi.nlm.nih.gov/7975354/
  28. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic united states national health and nutrition examination survey. Alimentary Pharmacol Therapeutics. 2015; 41: 65-76. PubMed: https://pubmed.ncbi.nlm.nih.gov/25376360/
  29. Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine. 2018; 97: e0214. PubMed: https://pubmed.ncbi.nlm.nih.gov/29595666/
  30. Ferreira VSG, Pernambuco RB, Lopes EP, Morais CN, Rodrigues MC, et al. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2010; 54: 362-368. PubMed: https://pubmed.ncbi.nlm.nih.gov/20625647/
  31. Sung KC, Cha SC, Sung JW, So MS, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutrit Metabol Cardiovasc Dis. 2014; 24: 256-262. PubMed: https://pubmed.ncbi.nlm.nih.gov/24361070/
  32. Huh JH, Kim KJ, Kim SU, Han SH, Han KH, et al. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism. 2017; 66: 23-31. PubMed: https://pubmed.ncbi.nlm.nih.gov/27923446/
  33. Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Review of Gastroenterol Hepatol. 2018; 12: 491-502. PubMed: https://pubmed.ncbi.nlm.nih.gov/29609501/
  34. Lonardo A, Ballestri S, Targher G. “Not all forms of NAFLD were created equal”. Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis? Atherosclerosis. 2017; 257: 253-255. PubMed: https://pubmed.ncbi.nlm.nih.gov/28126321/
  35. Käräjämäki AJ, Hukkanen J, Kauma H, Kesäniemi YA, Ukkola O. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study). Scandinavian J Clin Laboratory Investigation. 2020; 80: 106-113. PubMed: https://pubmed.ncbi.nlm.nih.gov/31851849/
  36. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta‐analysis. Hepatology. 2011; 54: 1082-1090. PubMed: https://pubmed.ncbi.nlm.nih.gov/21618575/

Similar Articles

Recently Viewed

  • Calciphylaxis in Hemodialysis
    Luca Sgarabotto*, Paola Baldini Anastasio, Nicola Marchionna and Monica Zanella Luca Sgarabotto*, Paola Baldini Anastasio, Nicola Marchionna, Monica Zanella. Calciphylaxis in Hemodialysis. J Clini Nephrol. 2023: doi: 10.29328/journal.jcn.1001107; 7: 044-046
  • Microbial Conversion and Utilization of CO2
    Ge-Ge Wang, Yuan Zhang, Xiao-Yan Wang* and Gen-Lin Zhang Ge-Ge Wang, Yuan Zhang, Xiao-Yan Wang*, Gen-Lin Zhang. Microbial Conversion and Utilization of CO2. Ann Civil Environ Eng. 2023: doi: 10.29328/journal.acee.1001055; 7: 045-060
  • Sanitary update on wheat in Argentina
    Enrique Javier Alberione* Enrique Javier Alberione*. Sanitary update on wheat in Argentina. J Plant Sci Phytopathol. 2022: doi: 10.29328/journal.jpsp.1001080; 6: 087-090
  • Risk factors for esophageal strictures in children and adolescents with eosinophilic esophagitis
    Vijayalakshmi Kory*, Thirumazhisai S Gunasekaran, Kumail Hussain, Tiffany Patton, Yi Li, Cheryl LeFaiver and James Berman Vijayalakshmi Kory*,Thirumazhisai S Gunasekaran,Kumail Hussain,Tiffany Patton,Yi Li,Cheryl LeFaiver,James Berman. Risk factors for esophageal strictures in children and adolescents with eosinophilic esophagitis. J Adv Pediatr Child Health. 2022: doi: 10.29328/journal.japch.1001050; 5: 033-038
  • A study to correlate the central corneal thickness to the severity of diabetic retinopathy and HbA1c levels in type 2 diabetes mellitus
    Neha Nargis*, Seema Channabasappa, Nischala Balakrishna and Singri Niharika Neha Nargis*,Seema Channabasappa,Nischala Balakrishna,Singri Niharika. A study to correlate the central corneal thickness to the severity of diabetic retinopathy and HbA1c levels in type 2 diabetes mellitus. Int J Clin Exp Ophthalmol. 2021: doi: 10.29328/journal.ijceo.1001041; 5: 029-038

Read More

Most Viewed

Read More

Help ?